Article Details

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of “Hold” by Analysts

Retrieved on: 2022-11-11 07:04:07

Tags for this article:

Click the tags to see associated articles and topics

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of “Hold” by Analysts. View article details on hiswai:

Excerpt

AQR Capital Management LLC now owns 862,168 shares of the biopharmaceutical company's stock worth $304,000 after acquiring an additional 677,703 ...

Article found on: reporter.am

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up